http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 14 May 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html <p>OXFORD, United Kingdom and MADISON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- OrganOx, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer &amp; President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo http://www.streetinsider.com/Press+Releases/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html Thu, 14 May 2026 08:00:00 -0400 4543 A.50214830 A.50214881 O.04697602 O.05105687 O.71961715 TRUMY http://www.streetinsider.com/Press+Releases/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html <p>OXFORD, United Kingdom and MADISON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- OrganOx, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer &amp; President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo http://www.streetinsider.com/Press+Releases/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html Thu, 14 May 2026 08:00:00 -0400 4543 A.50214830 A.50214881 O.04697602 O.05105687 O.71961715 TRUMY http://www.streetinsider.com/Press+Releases/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html <p>OXFORD, United Kingdom and MADISON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- OrganOx, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer &amp; President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo http://www.streetinsider.com/Press+Releases/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html Thu, 14 May 2026 08:00:00 -0400 4543 A.50214830 A.50214881 O.04697602 O.05105687 O.71961715 TRUMY http://www.streetinsider.com/Press+Releases/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html <p>OXFORD, United Kingdom and MADISON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- OrganOx, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer &amp; President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo http://www.streetinsider.com/Press+Releases/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html Thu, 14 May 2026 08:00:00 -0400 4543 A.50214830 A.50214881 O.04697602 O.05105687 O.71961715 TRUMY http://www.streetinsider.com/Press+Releases/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html <p>OXFORD, United Kingdom and MADISON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- OrganOx, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer &amp; President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo http://www.streetinsider.com/Press+Releases/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html Thu, 14 May 2026 08:00:00 -0400 4543 A.50214830 A.50214881 O.04697602 O.05105687 O.71961715 TRUMY http://www.streetinsider.com/Press+Releases/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html <p>OXFORD, United Kingdom and MADISON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- OrganOx, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer &amp; President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo http://www.streetinsider.com/Press+Releases/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html Thu, 14 May 2026 08:00:00 -0400 4543 A.50214830 A.50214881 O.04697602 O.05105687 O.71961715 TRUMY http://www.streetinsider.com/Press+Releases/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html <p>OXFORD, United Kingdom and MADISON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- OrganOx, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer &amp; President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo http://www.streetinsider.com/Press+Releases/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html Thu, 14 May 2026 08:00:00 -0400 4543 A.50214830 A.50214881 O.04697602 O.05105687 O.71961715 TRUMY http://www.streetinsider.com/Globe+Newswire/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html <p>OXFORD, United Kingdom and MADISON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- OrganOx, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer &amp; President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo http://www.streetinsider.com/Globe+Newswire/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html Thu, 14 May 2026 08:00:00 -0400 4543 A.50214830 A.50214881 O.04697602 O.05105687 O.71961715 TRUMY http://www.streetinsider.com/Globe+Newswire/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html <p>OXFORD, United Kingdom and MADISON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- OrganOx, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer &amp; President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo http://www.streetinsider.com/Globe+Newswire/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html Thu, 14 May 2026 08:00:00 -0400 4543 A.50214830 A.50214881 O.04697602 O.05105687 O.71961715 TRUMY http://www.streetinsider.com/Globe+Newswire/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html <p>OXFORD, United Kingdom and MADISON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- OrganOx, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer &amp; President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo http://www.streetinsider.com/Globe+Newswire/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html Thu, 14 May 2026 08:00:00 -0400 4543 A.50214830 A.50214881 O.04697602 O.05105687 O.71961715 TRUMY http://www.streetinsider.com/Globe+Newswire/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html <p>OXFORD, United Kingdom and MADISON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- OrganOx, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer &amp; President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo http://www.streetinsider.com/Globe+Newswire/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html Thu, 14 May 2026 08:00:00 -0400 4543 A.50214830 A.50214881 O.04697602 O.05105687 O.71961715 TRUMY http://www.streetinsider.com/Globe+Newswire/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html <p>OXFORD, United Kingdom and MADISON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- OrganOx, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer &amp; President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo http://www.streetinsider.com/Globe+Newswire/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html Thu, 14 May 2026 08:00:00 -0400 4543 A.50214830 A.50214881 O.04697602 O.05105687 O.71961715 TRUMY http://www.streetinsider.com/Globe+Newswire/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html <p>OXFORD, United Kingdom and MADISON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- OrganOx, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer &amp; President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo http://www.streetinsider.com/Globe+Newswire/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html Thu, 14 May 2026 08:00:00 -0400 4543 A.50214830 A.50214881 O.04697602 O.05105687 O.71961715 TRUMY http://www.streetinsider.com/Globe+Newswire/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html <p>OXFORD, United Kingdom and MADISON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- OrganOx, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer &amp; President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo http://www.streetinsider.com/Globe+Newswire/OrganOx+Announces+Appointment+of+Naoya+Iwata+as+CEO+%26amp%3B+President/26490214.html Thu, 14 May 2026 08:00:00 -0400 4543 A.50214830 A.50214881 O.04697602 O.05105687 O.71961715 TRUMY http://www.streetinsider.com/Press+Releases/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html <p>MELBOURNE, Australia , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced the first product launch of its patented evacuated blood collection technology, with the launch by Japanese medical device company, Terumo Corporation of its VenoJect II RAPClotTM blood collection tubes in the Japanese market.</p> <p>Q-Sera’s ecarin (RAPClot) technology involves using a certain class of proteins (prothrombin activators) originally identified from the venom of specific snakes to accelerate the clotting of blood in an improved blood collection tube to rapidly produce high quality serum for biochemical analysis, even from anticoagulated blood.</p> http://www.streetinsider.com/Press+Releases/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html Thu, 19 Feb 2026 04:35:00 -0400 4543 A.16494595 A.39326363 O.05105687 O.16738878 O.18286449 TRUMY http://www.streetinsider.com/Press+Releases/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html <p>MELBOURNE, Australia , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced the first product launch of its patented evacuated blood collection technology, with the launch by Japanese medical device company, Terumo Corporation of its VenoJect II RAPClotTM blood collection tubes in the Japanese market.</p> <p>Q-Sera’s ecarin (RAPClot) technology involves using a certain class of proteins (prothrombin activators) originally identified from the venom of specific snakes to accelerate the clotting of blood in an improved blood collection tube to rapidly produce high quality serum for biochemical analysis, even from anticoagulated blood.</p> http://www.streetinsider.com/Press+Releases/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html Thu, 19 Feb 2026 04:35:00 -0400 4543 A.16494595 A.39326363 O.05105687 O.16738878 O.18286449 TRUMY http://www.streetinsider.com/Press+Releases/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html <p>MELBOURNE, Australia , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced the first product launch of its patented evacuated blood collection technology, with the launch by Japanese medical device company, Terumo Corporation of its VenoJect II RAPClotTM blood collection tubes in the Japanese market.</p> <p>Q-Sera’s ecarin (RAPClot) technology involves using a certain class of proteins (prothrombin activators) originally identified from the venom of specific snakes to accelerate the clotting of blood in an improved blood collection tube to rapidly produce high quality serum for biochemical analysis, even from anticoagulated blood.</p> http://www.streetinsider.com/Press+Releases/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html Thu, 19 Feb 2026 04:35:00 -0400 4543 A.16494595 A.39326363 O.05105687 O.16738878 O.18286449 TRUMY http://www.streetinsider.com/Press+Releases/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html <p>MELBOURNE, Australia , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced the first product launch of its patented evacuated blood collection technology, with the launch by Japanese medical device company, Terumo Corporation of its VenoJect II RAPClotTM blood collection tubes in the Japanese market.</p> <p>Q-Sera’s ecarin (RAPClot) technology involves using a certain class of proteins (prothrombin activators) originally identified from the venom of specific snakes to accelerate the clotting of blood in an improved blood collection tube to rapidly produce high quality serum for biochemical analysis, even from anticoagulated blood.</p> http://www.streetinsider.com/Press+Releases/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html Thu, 19 Feb 2026 04:35:00 -0400 4543 A.16494595 A.39326363 O.05105687 O.16738878 O.18286449 TRUMY http://www.streetinsider.com/Press+Releases/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html <p>MELBOURNE, Australia , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced the first product launch of its patented evacuated blood collection technology, with the launch by Japanese medical device company, Terumo Corporation of its VenoJect II RAPClotTM blood collection tubes in the Japanese market.</p> <p>Q-Sera’s ecarin (RAPClot) technology involves using a certain class of proteins (prothrombin activators) originally identified from the venom of specific snakes to accelerate the clotting of blood in an improved blood collection tube to rapidly produce high quality serum for biochemical analysis, even from anticoagulated blood.</p> http://www.streetinsider.com/Press+Releases/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html Thu, 19 Feb 2026 04:35:00 -0400 4543 A.16494595 A.39326363 O.05105687 O.16738878 O.18286449 TRUMY http://www.streetinsider.com/Press+Releases/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html <p>MELBOURNE, Australia , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced the first product launch of its patented evacuated blood collection technology, with the launch by Japanese medical device company, Terumo Corporation of its VenoJect II RAPClotTM blood collection tubes in the Japanese market.</p> <p>Q-Sera’s ecarin (RAPClot) technology involves using a certain class of proteins (prothrombin activators) originally identified from the venom of specific snakes to accelerate the clotting of blood in an improved blood collection tube to rapidly produce high quality serum for biochemical analysis, even from anticoagulated blood.</p> http://www.streetinsider.com/Press+Releases/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html Thu, 19 Feb 2026 04:35:00 -0400 4543 A.16494595 A.39326363 O.05105687 O.16738878 O.18286449 TRUMY http://www.streetinsider.com/Press+Releases/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html <p>MELBOURNE, Australia , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced the first product launch of its patented evacuated blood collection technology, with the launch by Japanese medical device company, Terumo Corporation of its VenoJect II RAPClotTM blood collection tubes in the Japanese market.</p> <p>Q-Sera’s ecarin (RAPClot) technology involves using a certain class of proteins (prothrombin activators) originally identified from the venom of specific snakes to accelerate the clotting of blood in an improved blood collection tube to rapidly produce high quality serum for biochemical analysis, even from anticoagulated blood.</p> http://www.streetinsider.com/Press+Releases/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html Thu, 19 Feb 2026 04:35:00 -0400 4543 A.16494595 A.39326363 O.05105687 O.16738878 O.18286449 TRUMY http://www.streetinsider.com/Globe+Newswire/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html <p>MELBOURNE, Australia , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced the first product launch of its patented evacuated blood collection technology, with the launch by Japanese medical device company, Terumo Corporation of its VenoJect II RAPClotTM blood collection tubes in the Japanese market.</p> <p>Q-Sera’s ecarin (RAPClot) technology involves using a certain class of proteins (prothrombin activators) originally identified from the venom of specific snakes to accelerate the clotting of blood in an improved blood collection tube to rapidly produce high quality serum for biochemical analysis, even from anticoagulated blood.</p> http://www.streetinsider.com/Globe+Newswire/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html Thu, 19 Feb 2026 04:35:00 -0400 4543 A.16494595 A.39326363 O.05105687 O.16738878 O.18286449 TRUMY http://www.streetinsider.com/Globe+Newswire/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html <p>MELBOURNE, Australia , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced the first product launch of its patented evacuated blood collection technology, with the launch by Japanese medical device company, Terumo Corporation of its VenoJect II RAPClotTM blood collection tubes in the Japanese market.</p> <p>Q-Sera’s ecarin (RAPClot) technology involves using a certain class of proteins (prothrombin activators) originally identified from the venom of specific snakes to accelerate the clotting of blood in an improved blood collection tube to rapidly produce high quality serum for biochemical analysis, even from anticoagulated blood.</p> http://www.streetinsider.com/Globe+Newswire/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html Thu, 19 Feb 2026 04:35:00 -0400 4543 A.16494595 A.39326363 O.05105687 O.16738878 O.18286449 TRUMY http://www.streetinsider.com/Globe+Newswire/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html <p>MELBOURNE, Australia , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced the first product launch of its patented evacuated blood collection technology, with the launch by Japanese medical device company, Terumo Corporation of its VenoJect II RAPClotTM blood collection tubes in the Japanese market.</p> <p>Q-Sera’s ecarin (RAPClot) technology involves using a certain class of proteins (prothrombin activators) originally identified from the venom of specific snakes to accelerate the clotting of blood in an improved blood collection tube to rapidly produce high quality serum for biochemical analysis, even from anticoagulated blood.</p> http://www.streetinsider.com/Globe+Newswire/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html Thu, 19 Feb 2026 04:35:00 -0400 4543 A.16494595 A.39326363 O.05105687 O.16738878 O.18286449 TRUMY http://www.streetinsider.com/Globe+Newswire/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html <p>MELBOURNE, Australia , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced the first product launch of its patented evacuated blood collection technology, with the launch by Japanese medical device company, Terumo Corporation of its VenoJect II RAPClotTM blood collection tubes in the Japanese market.</p> <p>Q-Sera’s ecarin (RAPClot) technology involves using a certain class of proteins (prothrombin activators) originally identified from the venom of specific snakes to accelerate the clotting of blood in an improved blood collection tube to rapidly produce high quality serum for biochemical analysis, even from anticoagulated blood.</p> http://www.streetinsider.com/Globe+Newswire/Q-Sera+announces+the+first+launch+of+blood+collection+tubes+using+its+patented+Rapclot+technology+in+Japan%2C+opening+opportunities+for+additional+global+partnerships/26025003.html Thu, 19 Feb 2026 04:35:00 -0400 4543 A.16494595 A.39326363 O.05105687 O.16738878 O.18286449 TRUMY